Aesther Healthcare Acquisition Corp.
AEHAW
NASDAQ Global Market0.16
USD
+0.01
- -
CIK
0001869974
Return %
Stock
S&P500
1Y
-36.04
18.21
3Y
-68.65
63.29
5Y
-68.65
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- CIK
- 0001869974
- Similar Companies
- Business
- Aesther Healthcare Acquisition Corp. Aesther Healthcare Acquisition Corp. (AEHAW) is a special purpose acquisition company formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the pharmaceutical and medical devices sectors; its core offerings include identifying and pursuing targets in healthcare services, biotechnology, medical technology, and related innovative enterprises. Incorporated in 2021 and headquartered at 515 Madison Avenue, Suite 8078, New York, New York, the company focuses on early- and growth-stage healthcare firms to drive shareholder value through strategic combinations, with operations centered in the United States. In a major development completed on February 14, 2023, Aesther Healthcare Acquisition Corp. was acquired by Ocean Biomedical, Inc. Ocean Biomedical, Inc. through a reverse merger transaction valued at a pro forma enterprise of approximately $345 million, resulting in the combined entity adopting the Ocean Biomedical name and trading its common stock and warrants under new Nasdaq symbols OCEA and OCEAW while retaining AEHAW warrants as legacy securities exercisable into the post-merger structure; this deal, announced in August 2022 and supported by backstop agreements totaling up to $80 million from Vellar Opportunity Fund and others plus a $75 million common stock purchase commitment from White Lion Capital, accelerated Ocean Biomedical's pipeline in oncology, fibrosis, and infectious diseases including malaria vaccines backed by $123.9 million in grants.